OKYO OKYO Pharma Limited
OKYO Pharma Limited (OKYO) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
Where they traded
Last open-market purchase: July 27, 2026 , by Patil Rajkumar V. .
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Patil Rajkumar V. | Chief Scientific Officer | Buy | 3,363 | $1.49 | $5.0K | 20,030 | |
| Dempsey Robert John | CHIEF EXECUTIVE OFFICER | Buy | 15,000 | $1.54 | $23.1K | 15,000 | |
| CERRONE GABRIELE M | Director | Buy | 22,500 | $1.45 | $32.6K | 10,873,916 | |
| Mantelli Flavio | CHIEF MEDICAL OFFICER | Buy | 20,000 | $1.40 | $28.0K | 20,000 | |
| BRANCACCIO JOHN P | Director | Buy | 5,000 | $1.48 | $7.4K | 35,201 | |
| JACOB GARY S | CHIEF DEVELOPMENT OFFICER | Buy | 3,500 | $1.40 | $4.9K | 112,420 | |
| CERRONE GABRIELE M | Director | Buy | 25,000 | $1.40 | $35.0K | 10,851,416 |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.